Picture EBD Group BioPharm America 2019 Boston September 600x60px
Organisation › Details

2-BBB Medicines (Group)

to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory disorders, by combining existing drugs with the G-Technology, to-BBB's proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology for drugs that are unable to reach the brain at systemically tolerable therapeutic doses. to-BBB is applying the G-Technology to enhance the delivery of doxorubicin to the brain for the treatment of brain cancer as its internal lead product 2B3-101, which is currently being tested in a phase I/IIa trial in patients with primary brain tumors as well as patients with brain metastases. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM). *


Period Start 2017-03-28 restart before
  Today BBB Therapeutics (Group)
  Predecessor BBB Therapeutics (Group)
Products Industry drug delivery technology (drug formulation technology)
  Industry 2 CNS drug
Person Person van Weperen, Willem W. (Prosensa 201406– CCO before to-BBB 200902–201406 CEO before Genzyme Netherlands)
Region Region Leiden
  Country Netherlands
  Street 15 J.H. Oortweg
  City 2333 CH Leiden
    Address record changed: 2017-10-13
Basic data Employees B: 11 to 50 (2014-10-20)
    * Document for �About Section�: to-BBB Technologies B.V.. (4/25/13). "Press Release: to-BBB Closes EUR 2.5 Million Financing Round to Broaden Clinical Brain Tumor Study". Leiden.
Record changed: 2018-09-12


Picture [LSUS] – The Business Web Portal 600x60px

More documents for 2-BBB Medicines (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top